FDA Expands Imbruvica Use for Non-Hodgkin Lymphoma

Imbruvica (ibrutinib) can now be prescribed for patients with Waldenström’s macroglobulinemia (WM), a rare form of cancer that begins in the body’s immune system
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news